Free Trial
→ FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025 (From Colonial Metals) (Ad) Buy SWTX Stock  Free SWTX Stock Alerts

SpringWorks Therapeutics (SWTX) Financials

SpringWorks Therapeutics logo
$41.16 -0.06 (-0.13%)
As of 10:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for SpringWorks Therapeutics

Annual Income Statements for SpringWorks Therapeutics

This table shows SpringWorks Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -18 -51 -46 -174 -277 -325 -258
Consolidated Net Income / (Loss)		 -18 -58 -46 -174 -277 -325 -258
Net Income / (Loss) Continuing Operations		 -18 -114 -46 -174 -277 -325 -258
Total Pre-Tax Income 		-18 -115 -45 -173 -275 -320 -252
Total Operating Income		 -18 -59 -46 -173 -281 -343 -278
Total Gross Profit		 0.00 0.00 35 0.00 0.00 5.03 179
Total Revenue		 0.00 0.00 35 0.00 0.00 5.45 192
Operating Revenue		 0.00 0.00 35 0.00 0.00 5.45 192
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.42 13
Operating Cost of Revenue		 - - - 0.00 0.00 0.42 13
Total Operating Expenses		 18 118 81 173 281 348 457
Selling, General & Admin Expense		 8.59 17 29 72 135 198 257
Research & Development Expense		 9.90 43 52 102 146 150 201
Total Other Income / (Expense), net		 0.68 3.55 1.36 0.55 6.15 23 26
Interest & Investment Income		 0.68 3.55 - 0.55 6.15 23 26
Other Gains / (Losses), net		 0.00 0.93 -0.61 -0.99 -2.89 -5.04 -6.00
Basic Earnings per Share		 ($52.24) - ($1.05) ($3.59) ($5.21) ($5.15) ($3.48)
Weighted Average Basic Shares Outstanding		 0.00 13.27M 43.30M 48.50M 53.29M 63.12M 74.13M
Diluted Earnings per Share		 ($52.24) - ($1.05) ($3.59) ($5.21) ($5.15) ($3.48)
Weighted Average Diluted Shares Outstanding		 0.00 13.27M 43.30M 48.50M 53.29M 63.12M 74.13M
Weighted Average Basic & Diluted Shares Outstanding		 341.01K 0.00 0.00 49.34M 62.50M 73.79M 74.94M

Quarterly Income Statements for SpringWorks Therapeutics

This table shows SpringWorks Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -72 -74 -73 -78 -79 -94 -87 -40 -54 -77
Consolidated Net Income / (Loss)		 -72 -74 -73 -78 -79 -94 -87 -40 -54 -77
Net Income / (Loss) Continuing Operations		 -72 -74 -73 -78 -79 -94 -87 -40 -54 -77
Total Pre-Tax Income 		-71 -73 -72 -77 -78 -92 -86 -38 -52 -76
Total Operating Income		 -72 -78 -78 -83 -84 -98 -94 -45 -58 -81
Total Gross Profit		 0.00 - 0.00 0.00 0.00 5.03 20 57 46 56
Total Revenue		 0.00 - 0.00 0.00 0.00 5.45 21 60 49 62
Operating Revenue		 - - 0.00 0.00 0.00 5.45 21 60 49 62
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 0.42 1.20 2.45 3.34 5.55
Operating Cost of Revenue		 - - 0.00 0.00 0.00 0.42 1.20 2.45 3.34 5.55
Total Operating Expenses		 72 78 78 83 84 103 114 102 104 137
Selling, General & Admin Expense		 36 41 44 47 47 60 60 58 62 77
Research & Development Expense		 36 38 34 36 37 44 54 44 42 60
Total Other Income / (Expense), net		 0.84 4.96 5.56 5.83 5.59 5.98 7.57 6.78 6.22 5.44
Interest & Investment Income		 0.91 4.67 5.56 5.83 5.59 5.98 7.57 6.78 6.22 5.44
Other Gains / (Losses), net		 -1.49 -0.68 -1.28 -0.90 -1.02 -1.84 -1.03 -1.78 -1.81 -1.39
Basic Earnings per Share		 ($1.37) - ($1.18) ($1.25) ($1.27) ($1.45) ($1.18) ($0.54) ($0.72) ($1.04)
Weighted Average Basic Shares Outstanding		 52.90M 53.29M 62.33M 62.46M 62.52M 63.12M 73.77M 74.12M 74.26M 74.13M
Diluted Earnings per Share		 ($1.37) - ($1.18) ($1.25) ($1.27) ($1.45) ($1.18) ($0.54) ($0.72) ($1.04)
Weighted Average Diluted Shares Outstanding		 52.90M 53.29M 62.33M 62.46M 62.52M 63.12M 73.77M 74.12M 74.26M 74.13M
Weighted Average Basic & Diluted Shares Outstanding		 - 62.50M 62.52M 62.57M 62.58M 73.79M 74.09M 74.27M 74.39M 74.94M

Annual Cash Flow Statements for SpringWorks Therapeutics

This table details how cash moves in and out of SpringWorks Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 36 282 -181 -43 -36 109 -106
Net Cash From Operating Activities		 -14 -47 -32 -128 -162 -223 -176
Net Cash From Continuing Operating Activities		 -14 -47 -32 -128 -162 -223 -176
Net Income / (Loss) Continuing Operations		 -18 -58 -46 -174 -277 -325 -258
Consolidated Net Income / (Loss)		 -18 -58 -46 -174 -277 -325 -258
Depreciation Expense		 0.02 0.19 0.35 0.49 0.77 1.67 3.47
Non-Cash Adjustments To Reconcile Net Income		 1.07 5.72 12 40 77 101 117
Changes in Operating Assets and Liabilities, net		 2.56 4.95 1.35 5.12 38 -0.58 -38
Net Cash From Investing Activities		 -0.29 -4.26 -419 84 -216 35 65
Net Cash From Continuing Investing Activities		 -0.29 -4.26 -419 84 -216 35 65
Purchase of Property, Plant & Equipment		 -0.29 -0.67 -0.64 -2.02 -10 -7.39 -4.45
Acquisitions		 0.00 -3.59 -3.50 0.00 -4.20 -2.80 -24
Purchase of Investments		 0.00 0.00 -443 -305 -481 -576 -285
Sale and/or Maturity of Investments		 0.00 0.00 28 391 280 621 379
Net Cash From Financing Activities		 50 334 270 1.16 341 297 4.76
Net Cash From Continuing Financing Activities		 50 334 270 1.16 341 297 4.76
Repurchase of Common Equity		 - - 0.00 0.00 -1.34 -2.80 -8.44
Issuance of Common Equity		 0.00 170 270 0.00 340 299 0.00
Other Financing Activities, net		 0.00 0.02 0.89 1.16 1.98 0.14 13

Quarterly Cash Flow Statements for SpringWorks Therapeutics

This table details how cash moves in and out of SpringWorks Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 407 -409 35 13 -16 77 -58 -38 4.56 -15
Net Cash From Operating Activities		 -20 -54 -62 -48 -50 -63 -79 -42 -25 -30
Net Cash From Continuing Operating Activities		 -20 -54 -62 -48 -50 -63 -79 -41 -26 -30
Net Income / (Loss) Continuing Operations		 -72 -74 -73 -78 -79 -94 -87 -40 -54 -77
Consolidated Net Income / (Loss)		 -72 -74 -73 -78 -79 -94 -87 -40 -54 -77
Depreciation Expense		 0.21 0.26 0.25 0.38 0.49 0.54 0.73 0.84 0.88 1.02
Non-Cash Adjustments To Reconcile Net Income		 20 20 25 24 25 27 32 29 28 28
Changes in Operating Assets and Liabilities, net		 32 -0.17 -14 6.06 3.27 3.70 -24 -31 -1.18 19
Net Cash From Investing Activities		 86 -355 99 61 35 -159 21 0.29 29 14
Net Cash From Continuing Investing Activities		 86 -355 99 61 35 -159 21 0.29 29 14
Purchase of Property, Plant & Equipment		 -3.53 -1.76 -2.98 -3.09 -3.62 2.30 -0.58 -0.98 -1.85 -1.05
Acquisitions		 - - -2.80 - - - -8.24 -11 - -5.00
Purchase of Investments		 - -413 -68 -144 -97 -266 -74 -86 -45 -81
Sale and/or Maturity of Investments		 90 60 173 208 135 105 104 98 76 101
Net Cash From Financing Activities		 340 0.30 -1.85 -0.34 -0.24 299 -0.55 3.37 1.29 0.65
Net Cash From Continuing Financing Activities		 340 0.30 -1.85 -0.34 -0.24 299 -0.55 3.37 1.29 0.65
Repurchase of Common Equity		 -0.21 - -1.93 -0.35 -0.26 -0.25 -6.50 -0.92 -0.50 -0.52
Other Financing Activities, net		 0.38 0.30 0.08 0.01 0.02 0.02 5.95 4.29 1.79 1.18

Annual Balance Sheets for SpringWorks Therapeutics

This table presents SpringWorks Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Total Assets		 48 335 576 452 630 726 587
Total Current Assets		 47 331 513 383 600 501 380
Cash & Equivalents		 46 328 147 104 67 176 70
Short-Term Investments		 - 0.00 361 270 525 303 238
Accounts Receivable		 - - - - 0.00 5.93 46
Inventories, net		 - - - - 0.00 3.10 10
Prepaid Expenses		 1.38 3.71 4.91 9.41 7.55 13 16
Plant, Property, & Equipment, net		 0.32 0.80 1.08 3.19 14 18 20
Total Noncurrent Assets		 1.04 2.68 62 66 17 207 187
Long-Term Investments		 0.00 0.98 57 62 8.99 185 158
Other Noncurrent Operating Assets		 1.04 1.70 4.51 4.28 7.92 22 29
Total Liabilities & Shareholders' Equity		 48 335 576 452 630 726 587
Total Liabilities		 4.83 13 19 30 72 100 106
Total Current Liabilities		 3.68 12 18 30 51 78 100
Accounts Payable		 0.77 2.65 1.35 3.43 8.01 7.40 12
Accrued Expenses		 2.57 8.95 15 25 39 66 86
Current Deferred Revenue		 0.34 0.36 - 0.00 3.31 4.14 0.00
Other Current Liabilities		 - 0.00 1.38 1.16 0.48 1.06 1.73
Total Noncurrent Liabilities		 1.15 0.79 1.52 0.13 21 21 6.18
Noncurrent Deferred Revenue		 1.15 0.79 - 0.00 16 15 0.00
Other Noncurrent Operating Liabilities		 - 0.00 1.52 0.13 4.77 6.00 6.18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -19 322 557 422 558 626 481
Total Preferred & Common Equity		 -19 322 557 422 558 626 481
Preferred Stock		 2.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -21 322 557 422 558 626 481
Common Stock		 1.07 395 676 715 1,130 1,524 1,647
Retained Earnings		 -22 -73 -119 -293 -570 -895 -1,153
Treasury Stock		 - - - 0.00 -1.34 -4.14 -13
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.04 -0.31 -0.77 1.19 0.30

Quarterly Balance Sheets for SpringWorks Therapeutics

This table presents SpringWorks Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 569 517 468 657 617 609
Total Current Assets		 538 484 432 472 431 435
Cash & Equivalents		 102 115 99 118 80 84
Short-Term Investments		 426 362 324 319 304 292
Accounts Receivable		 - - - 16 25 33
Inventories, net		 - - - 5.22 7.72 9.83
Prepaid Expenses		 9.52 7.19 9.96 14 15 16
Plant, Property, & Equipment, net		 16 18 21 18 18 19
Total Noncurrent Assets		 16 15 14 167 168 154
Long-Term Investments		 5.71 4.81 3.79 146 145 127
Other Noncurrent Operating Assets		 10 10 11 21 22 27
Total Liabilities & Shareholders' Equity		 569 517 468 657 617 609
Total Liabilities		 62 66 73 89 61 76
Total Current Liabilities		 38 42 50 69 55 71
Accounts Payable		 6.99 3.45 5.55 7.01 7.89 9.65
Accrued Expenses		 29 35 40 56 46 60
Current Deferred Revenue		 1.69 2.36 3.24 4.65 0.00 0.00
Other Current Liabilities		 0.39 0.81 1.16 0.98 0.96 1.23
Total Noncurrent Liabilities		 25 24 22 20 6.10 5.68
Noncurrent Deferred Revenue		 18 17 16 15 0.00 0.00
Other Noncurrent Operating Liabilities		 6.66 6.80 6.17 5.58 6.10 5.68
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 507 451 395 567 557 533
Total Preferred & Common Equity		 507 451 395 567 557 533
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 507 451 395 567 557 533
Common Stock		 1,154 1,177 1,200 1,561 1,591 1,619
Retained Earnings		 -643 -721 -801 -982 -1,022 -1,076
Treasury Stock		 -3.27 -3.62 -3.89 -11 -12 -12
Accumulated Other Comprehensive Income / (Loss)		 -0.16 -0.35 -0.31 -0.11 -0.52 1.61

Annual Metrics and Ratios for SpringWorks Therapeutics

This table displays calculated financial ratios and metrics derived from SpringWorks Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 3,417.33%
EBITDA Growth		 0.00% -219.62% 22.18% -276.45% -61.82% -21.95% 19.54%
EBIT Growth		 0.00% -220.37% 21.84% -274.67% -61.80% -22.21% 18.92%
NOPAT Growth		 0.00% -220.37% 21.80% -274.47% -61.80% -22.21% 18.92%
Net Income Growth		 0.00% -227.32% 21.84% -281.60% -59.52% -17.19% 20.60%
EPS Growth		 0.00% 0.00% 0.00% -241.90% -45.13% 1.15% 32.43%
Operating Cash Flow Growth		 0.00% -234.91% 32.15% -297.24% -26.34% -37.90% 21.18%
Free Cash Flow Firm Growth		 0.00% 0.00% 17.97% -284.99% -42.66% -46.86% -1.32%
Invested Capital Growth		 0.00% -214.14% -31.68% -53.11% -225.37% 10.89% 139.13%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 41.41%
EBITDA Q/Q Growth		 0.00% 0.00% 38.41% -63.08% 0.00% -6.13% 6.02%
EBIT Q/Q Growth		 0.00% 0.00% 38.20% -62.84% 0.00% -6.19% 5.80%
NOPAT Q/Q Growth		 0.00% 0.00% 38.16% -62.95% 0.00% -6.19% 5.80%
Net Income Q/Q Growth		 0.00% 0.00% 37.62% -63.19% 0.00% -6.61% 6.19%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.54%
Operating Cash Flow Q/Q Growth		 0.00% -38.18% 49.16% -92.31% 0.00% -3.97% 15.90%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -78.52% -871.97% -25.67% 7.06%
Invested Capital Q/Q Growth		 0.00% 0.00% -6.83% 22.92% 0.00% -22.41% -48.07%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 0.00% 0.00% 92.25% 93.45%
EBITDA Margin		 0.00% 0.00% -131.29% 0.00% 0.00% -6,266.68% -143.36%
Operating Margin		 0.00% 0.00% -132.35% 0.00% 0.00% -6,297.28% -145.17%
EBIT Margin		 0.00% 0.00% -132.28% 0.00% 0.00% -6,297.28% -145.17%
Profit (Net Income) Margin		 0.00% 0.00% -130.21% 0.00% 0.00% -5,968.50% -134.73%
Tax Burden Percent		 100.00% 50.73% 101.35% 100.57% 101.05% 101.57% 102.38%
Interest Burden Percent		 96.33% 194.01% 97.13% 99.69% 97.81% 93.31% 90.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -40.89% -31.89% -10.37% -35.51% -56.58% -54.90% -46.62%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,653.85%
Operating Return on Assets (OROA)		 0.00% 0.00% -10.16% 0.00% 0.00% -50.59% -42.36%
Return on Assets (ROA)		 0.00% 0.00% -10.01% 0.00% 0.00% -47.95% -39.32%
Return on Common Equity (ROCE)		 20.07% -26.23% -10.37% -35.51% -56.58% -54.90% -46.62%
Return on Equity Simple (ROE_SIMPLE)		 91.97% -18.10% -8.18% -41.17% -49.70% -51.92% -53.65%
Net Operating Profit after Tax (NOPAT)		 -13 -41 -32 -121 -196 -240 -195
NOPAT Margin		 0.00% 0.00% -92.65% 0.00% 0.00% -4,408.10% -101.62%
Net Nonoperating Expense Percent (NNEP)		 -10.67% -9.00% -2.94% -10.48% -15.61% -13.43% -11.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -35.20% -38.34% -40.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 7.75% 6.55%
SG&A Expenses to Revenue		 0.00% 0.00% 84.19% 0.00% 0.00% 3,626.79% 133.96%
R&D to Revenue		 0.00% 0.00% 148.17% 0.00% 0.00% 2,762.75% 104.66%
Operating Expenses to Revenue		 0.00% 0.00% 232.35% 0.00% 0.00% 6,389.54% 238.62%
Earnings before Interest and Taxes (EBIT)		 -18 -59 -46 -173 -281 -343 -278
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -59 -46 -173 -280 -341 -275
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 5.14 6.35 7.23 2.30 3.65 5.59
Price to Tangible Book Value (P/TBV)		 0.00 5.14 6.35 7.23 2.30 3.65 5.59
Price to Revenue (P/Rev)		 0.00 0.00 101.05 0.00 0.00 419.34 14.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 148.14
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 84.88 0.00 0.00 297.34 11.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.02 -1.02 -1.02 -1.06 -1.07 -1.02
Leverage Ratio		 1.11 1.05 1.04 1.05 1.10 1.14 1.19
Compound Leverage Factor		 1.07 2.03 1.01 1.05 1.08 1.07 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 4.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 144.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -49.09% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 19.29 78.10 111.45 59.62 9.02 11.18 11.78
Noncontrolling Interest Sharing Ratio		 149.09% 17.76% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 12.79 27.68 29.15 12.78 11.75 6.41 3.81
Quick Ratio		 12.41 27.37 28.87 12.46 11.60 6.21 3.54
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -37 -30 -117 -167 -245 -248
Operating Cash Flow to CapEx		 -4,834.81% -7,081.19% -5,014.17% -6,343.11% -1,584.57% -3,016.86% -3,945.16%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.08 0.00 0.00 0.01 0.29
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 7.35
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 1.89
Fixed Asset Turnover		 0.00 0.00 37.43 0.00 0.00 0.35 10.18
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.05 1.28
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 49.69
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 193.62
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 6,662.55 285.66
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -6,662.55 -42.34
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -2.09 -6.56 -8.63 -13 -43 -38 15
Invested Capital Turnover		 0.00 0.00 -4.61 0.00 0.00 -0.13 -16.43
Increase / (Decrease) in Invested Capital		 0.00 -4.47 -2.08 -4.59 -30 4.68 53
Enterprise Value (EV)		 181 1,327 2,971 2,617 685 1,620 2,221
Market Capitalization		 162 1,655 3,537 3,052 1,286 2,284 2,688
Book Value per Share		 ($62.70) $7.49 $11.42 $8.58 $10.47 $10.01 $6.47
Tangible Book Value per Share		 ($62.70) $7.49 $11.42 $8.58 $10.47 $10.01 $6.47
Total Capital		 44 322 557 422 558 626 481
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -46 -329 -566 -436 -601 -665 -466
Capital Expenditures (CapEx)		 0.29 0.67 0.64 2.02 10 7.39 4.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.30 -8.26 -13 -21 -44 -56 -28
Debt-free Net Working Capital (DFNWC)		 43 319 496 353 549 423 280
Net Working Capital (NWC)		 43 319 496 353 549 423 280
Net Nonoperating Expense (NNE)		 4.87 17 13 52 81 85 63
Net Nonoperating Obligations (NNO)		 -46 -329 -566 -436 -601 -665 -466
Total Depreciation and Amortization (D&A)		 0.02 0.19 0.35 0.49 0.77 1.67 3.47
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -36.27% 0.00% 0.00% -1,036.53% -14.36%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,416.54% 0.00% 0.00% 7,761.01% 146.39%
Net Working Capital to Revenue		 0.00% 0.00% 1,416.54% 0.00% 0.00% 7,761.01% 146.39%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($5.21) ($5.15) ($3.48)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 43.00M 48.98M 48.50M 53.29M 63.12M 74.13M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($5.21) ($5.15) ($3.48)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 43.00M 48.98M 48.50M 53.29M 63.12M 74.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.27M 43.30M 49.34M 62.50M 73.79M 74.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -41 -32 -121 -196 -240 -195
Normalized NOPAT Margin		 0.00% 0.00% -92.65% 0.00% 0.00% -4,408.10% -101.62%
Pre Tax Income Margin		 0.00% 0.00% -128.48% 0.00% 0.00% -5,876.01% -131.60%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.48% -0.86% -3.27%

Quarterly Metrics and Ratios for SpringWorks Therapeutics

This table displays calculated financial ratios and metrics derived from SpringWorks Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,029.96%
EBITDA Growth		 -75.35% 0.00% -25.82% -19.79% -16.62% -25.23% -20.34% 46.55% 31.67% 17.97%
EBIT Growth		 -75.36% 0.00% -26.01% -20.01% -16.97% -25.50% -20.89% 45.78% 31.03% 17.39%
NOPAT Growth		 -75.42% 0.00% -26.40% -20.06% -17.09% -25.50% -20.89% 45.78% 31.03% 17.39%
Net Income Growth		 0.00% 0.00% -18.80% -12.85% -9.74% -27.16% -19.02% 48.77% 32.61% 18.05%
EPS Growth		 0.00% 0.00% 0.00% 11.35% 7.30% 0.00% 0.00% 56.80% 43.31% 28.28%
Operating Cash Flow Growth		 27.20% 0.00% -26.97% -22.37% -157.40% -15.69% -27.68% 12.59% 49.71% 52.95%
Free Cash Flow Firm Growth		 -244.44% -648.07% 26.99% 9.29% 59.19% -192.92% -129.69% -106.43% -266.47% -49.79%
Invested Capital Growth		 100.00% -225.37% -315.09% -98.35% 0.00% 10.89% 45.37% 191.12% 192.24% 139.13%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 285.64% 184.36% -17.46% 24.84%
EBITDA Q/Q Growth		 -4.00% -9.21% 0.96% -6.49% -1.26% -17.27% 4.82% 52.71% -29.45% -40.78%
EBIT Q/Q Growth		 -4.03% -9.25% 0.96% -6.63% -1.38% -17.22% 4.60% 52.18% -28.98% -40.40%
NOPAT Q/Q Growth		 -3.95% -9.36% 0.96% -6.63% -1.38% -17.22% 4.60% 52.18% -28.98% -40.40%
Net Income Q/Q Growth		 -4.83% -2.47% 1.02% -6.14% -1.94% -18.74% 7.35% 54.32% -34.10% -44.40%
EPS Q/Q Growth		 2.84% 0.00% 0.00% -5.93% -1.60% -14.17% 18.62% 54.24% -33.33% -44.44%
Operating Cash Flow Q/Q Growth		 49.82% -176.47% -14.06% 22.66% -5.54% -24.26% -25.88% 47.05% 39.27% -16.24%
Free Cash Flow Firm Q/Q Growth		 -41.84% 62.70% -35.09% -26.91% 36.19% -167.76% -5.93% -14.06% -13.28% -9.45%
Invested Capital Q/Q Growth		 100.00% 0.00% 37.38% -11.69% -4.09% -22.41% 61.61% 286.30% 5.36% -48.07%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 92.25% 94.28% 95.89% 93.22% 90.98%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,797.78% -443.69% -73.79% -115.74% -130.51%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,807.66% -447.16% -75.20% -117.52% -132.16%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,807.66% -447.16% -75.20% -117.52% -132.16%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,731.63% -416.00% -66.83% -108.58% -125.59%
Tax Burden Percent		 102.10% 100.93% 101.77% 101.17% 101.31% 101.98% 101.19% 104.66% 103.50% 101.83%
Interest Burden Percent		 98.73% 93.68% 92.85% 92.97% 93.35% 93.93% 91.94% 84.91% 89.27% 93.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -56.58% -65.41% -76.67% -154.45% -54.90% -63.12% -59.72% -59.33% -46.62%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,030.38% -924.11% -1,653.85%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -14.52% -19.30% -11.42% -29.58% -38.57%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -13.91% -17.95% -10.15% -27.33% -36.65%
Return on Common Equity (ROCE)		 0.00% -56.58% -65.41% -76.67% -154.45% -54.90% -63.12% -59.72% -59.33% -46.62%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -57.02% -65.99% -77.22% 0.00% -59.75% -54.08% -51.66% 0.00%
Net Operating Profit after Tax (NOPAT)		 -50 -55 -54 -58 -59 -69 -66 -31 -41 -57
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,265.36% -313.01% -52.64% -82.26% -92.51%
Net Nonoperating Expense Percent (NNEP)		 -9.16% -3.72% -4.15% -4.85% -9.68% -4.01% -3.88% -1.68% -2.79% -3.60%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.84% - - - -11.01% - - - -11.84%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 7.75% 5.72% 4.11% 6.78% 9.02%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,098.51% 286.17% 96.83% 124.95% 125.26%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 801.40% 255.27% 74.27% 85.79% 97.87%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,899.91% 541.44% 171.10% 210.74% 223.13%
Earnings before Interest and Taxes (EBIT)		 -72 -78 -78 -83 -84 -98 -94 -45 -58 -81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -72 -78 -77 -82 -84 -98 -93 -44 -57 -80
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.30 3.17 3.63 3.66 3.65 5.43 5.01 4.47 5.59
Price to Tangible Book Value (P/TBV)		 0.00 2.30 3.17 3.63 3.66 3.65 5.43 5.01 4.47 5.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 419.34 116.44 32.38 17.56 14.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 82.51 64.96 148.14
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 297.34 94.43 26.24 13.85 11.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.06 -1.04 -1.06 -1.08 -1.07 -1.04 -1.00 -1.00 -1.02
Leverage Ratio		 1.06 1.10 1.10 1.14 1.18 1.14 1.14 1.13 1.16 1.19
Compound Leverage Factor		 1.05 1.03 1.02 1.06 1.11 1.08 1.05 0.96 1.04 1.11
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 10.08 14.52 13.47 9.92 12.30 18.88 25.95 16.87 12.88
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 11.75 14.24 11.55 8.60 6.41 6.85 7.91 6.16 3.81
Quick Ratio		 0.00 11.60 13.99 11.37 8.40 6.21 6.56 7.49 5.80 3.54
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -67 -25 -34 -43 -27 -74 -78 -89 -101 -110
Operating Cash Flow to CapEx		 -555.67% -3,086.56% -2,076.52% -1,548.28% -1,393.18% 0.00% -13,679.38% -4,286.15% -1,374.07% -2,804.18%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.04 0.15 0.25 0.29
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.35
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.89
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.35 1.56 4.73 6.73 10.18
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.05 0.23 0.72 0.98 1.28
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 49.69
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 193.62
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 6,662.55 1,573.39 507.75 373.96 285.66
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -6,662.55 -1,573.39 -507.75 -373.96 -42.34
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -43 -27 -30 -31 -38 -15 27 29 15
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.13 -1.27 -64.51 -111.47 -16.43
Increase / (Decrease) in Invested Capital		 17 -30 -20 -15 -31 4.68 12 57 60 53
Enterprise Value (EV)		 1,411 685 1,075 1,158 1,020 1,620 2,498 2,262 1,876 2,221
Market Capitalization		 1,411 1,286 1,609 1,639 1,447 2,284 3,080 2,791 2,380 2,688
Book Value per Share		 $0.00 $10.47 $8.11 $7.22 $6.31 $10.01 $7.69 $7.51 $7.17 $6.47
Tangible Book Value per Share		 $0.00 $10.47 $8.11 $7.22 $6.31 $10.01 $7.69 $7.51 $7.17 $6.47
Total Capital		 0.00 558 507 451 395 626 567 557 533 481
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -601 -534 -482 -426 -665 -582 -529 -504 -466
Capital Expenditures (CapEx)		 3.53 1.76 2.98 3.09 3.62 -2.30 0.58 0.98 1.85 1.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -44 -28 -35 -40 -56 -34 -7.06 -12 -28
Debt-free Net Working Capital (DFNWC)		 0.00 549 500 442 382 423 403 377 364 280
Net Working Capital (NWC)		 0.00 549 500 442 382 423 403 377 364 280
Net Nonoperating Expense (NNE)		 22 19 19 20 21 25 22 8.47 13 20
Net Nonoperating Obligations (NNO)		 0.00 -601 -534 -482 -426 -665 -582 -529 -504 -466
Total Depreciation and Amortization (D&A)		 0.21 0.26 0.25 0.38 0.49 0.54 0.73 0.84 0.88 1.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -1,036.53% -127.40% -8.19% -8.95% -14.36%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 7,761.01% 1,523.01% 437.22% 269.03% 146.39%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 7,761.01% 1,523.01% 437.22% 269.03% 146.39%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($1.25) ($1.27) ($1.45) ($1.18) ($0.54) ($0.72) ($1.04)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 53.29M 62.33M 62.46M 62.52M 63.12M 73.77M 74.12M 74.26M 74.13M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.25) ($1.27) ($1.45) ($1.18) ($0.54) ($0.72) ($1.04)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 53.29M 62.33M 62.46M 62.52M 63.12M 73.77M 74.12M 74.26M 74.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 62.50M 62.52M 62.57M 62.58M 73.79M 74.09M 74.27M 74.39M 74.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -50 -55 -54 -58 -59 -69 -66 -31 -41 -57
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,265.36% -313.01% -52.64% -82.26% -92.51%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,697.94% -411.12% -63.86% -104.91% -123.33%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.48% 0.00% -0.84% -0.84% -0.86% -2.17% -2.64% -2.97% -3.27%

Frequently Asked Questions About SpringWorks Therapeutics' Financials

When does SpringWorks Therapeutics's financial year end?

According to the most recent income statement we have on file, SpringWorks Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has SpringWorks Therapeutics' net income changed over the last 6 years?

SpringWorks Therapeutics' net income appears to be on an upward trend, with a most recent value of -$258.13 million in 2024, rising from -$17.81 million in 2018. The previous period was -$325.10 million in 2023.

What is SpringWorks Therapeutics's operating income?
SpringWorks Therapeutics's total operating income in 2024 was -$278.13 million, based on the following breakdown:
  • Total Gross Profit: $179.04 million
  • Total Operating Expenses: $457.17 million
How has SpringWorks Therapeutics revenue changed over the last 6 years?

Over the last 6 years, SpringWorks Therapeutics' total revenue changed from $0.00 in 2018 to $191.59 million in 2024, a change of 19,158,900,000.0%.

How much debt does SpringWorks Therapeutics have?

SpringWorks Therapeutics' total liabilities were at $106.17 million at the end of 2024, a 6.6% increase from 2023, and a 2,098.6% increase since 2018.

How much cash does SpringWorks Therapeutics have?

In the past 6 years, SpringWorks Therapeutics' cash and equivalents has ranged from $45.65 million in 2018 to $327.65 million in 2019, and is currently $69.75 million as of their latest financial filing in 2024.

How has SpringWorks Therapeutics' book value per share changed over the last 6 years?

Over the last 6 years, SpringWorks Therapeutics' book value per share changed from -62.70 in 2018 to 6.47 in 2024, a change of -110.3%.


Related Companies

This page (NASDAQ:SWTX) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...
Priority Gold | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored